The College of Physicians and Surgeons of Ontario (CPSO) paused enforcement of new safer-supply prescribing rules after being served with a legal challenge that included an injunction motion.
The CPSO approved the amendments Oct. 13 and expected physicians to transition to compliance by Nov. 16. The regulator announced the pause Nov. 13, three days before that transition date, while it responds to the motion.
Under the requirements, doctors would prescribe safer-supply medication only alongside opioid agonist therapy (OAT), with an in-person clinical assessment at least once a month. Doses would be taken under direct observation by a regulated health-care professional. Prescriptions would carry the instructions “safer supply” and “no carries,” meaning no take-home doses. The guidance does not name pharmacists as the only professionals who may supervise consumption.
In the CPSO’s definition, safer supply means prescribing short-acting, pharmaceutical-grade opioids to people with substance use disorder as an alternative to unregulated street drugs. OAT uses medications such as methadone, buprenorphine or slow-release oral morphine; the CPSO describes it as a first-line treatment for opioid use disorder. The regulator said the amendments were intended to reduce diversion and strengthen oversight.
During the pause, the CPSO advised physicians to keep meeting their professional responsibilities and make care decisions based on each patient’s circumstances. The Ontario College of Pharmacists (OCP) said pharmacists could continue dispensing prescriptions as written after judging them therapeutically appropriate and applying professional judgment.
The Canadian Press reported that the supervised-consumption requirements raised access concerns for rural Ontario residents and people with regular work schedules. The CPSO said it would provide updates as the situation develops. Neither the CPSO nor the OCP notice gave a next court date.



